117 related articles for article (PubMed ID: 11791013)
1. Epigallocatechin-3-gallate inhibits basic fibroblast growth factor-induced intracellular signaling transduction pathway in rat aortic smooth muscle cells.
Hwang KC; Lee KH; Jang Y; Yun YP; Chung KH
J Cardiovasc Pharmacol; 2002 Feb; 39(2):271-7. PubMed ID: 11791013
[TBL] [Abstract][Full Text] [Related]
2. Epigallocatechin suppression of proliferation of vascular smooth muscle cells: correlation with c-jun and JNK.
Lu LH; Lee SS; Huang HC
Br J Pharmacol; 1998 Jul; 124(6):1227-37. PubMed ID: 9720795
[TBL] [Abstract][Full Text] [Related]
3. Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172).
Ahn HY; Hadizadeh KR; Seul C; Yun YP; Vetter H; Sachinidis A
Mol Biol Cell; 1999 Apr; 10(4):1093-104. PubMed ID: 10198059
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of epigallocatechin 3-O-gallate on vascular smooth muscle cell hypertrophy induced by angiotensin II.
Zheng Y; Song HJ; Kim CH; Kim HS; Kim EG; Sachinidis A; Ahn HY
J Cardiovasc Pharmacol; 2004 Feb; 43(2):200-8. PubMed ID: 14716206
[TBL] [Abstract][Full Text] [Related]
5. Oxidation-triggered c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase pathways for apoptosis in human leukaemic cells stimulated by epigallocatechin-3-gallate (EGCG): a distinct pathway from those of chemically induced and receptor-mediated apoptosis.
Saeki K; Kobayashi N; Inazawa Y; Zhang H; Nishitoh H; Ichijo H; Saeki K; Isemura M; Yuo A
Biochem J; 2002 Dec; 368(Pt 3):705-20. PubMed ID: 12206715
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes.
Singh R; Ahmed S; Malemud CJ; Goldberg VM; Haqqi TM
J Orthop Res; 2003 Jan; 21(1):102-9. PubMed ID: 12507586
[TBL] [Abstract][Full Text] [Related]
7. (--)-epigallocatechin gallate enhances prostaglandin F2alpha-induced VEGF synthesis via upregulating SAPK/JNK activation in osteoblasts.
Tokuda H; Takai S; Matsushima-Nishiwaki R; Akamatsu S; Hanai Y; Hosoi T; Harada A; Ohta T; Kozawa O
J Cell Biochem; 2007 Apr; 100(5):1146-53. PubMed ID: 17031857
[TBL] [Abstract][Full Text] [Related]
8. The Green Tea Component (-)-Epigallocatechin-3-Gallate Sensitizes Primary Endothelial Cells to Arsenite-Induced Apoptosis by Decreasing c-Jun N-Terminal Kinase-Mediated Catalase Activity.
Kim JY; Choi JY; Lee HJ; Byun CJ; Park JH; Park JH; Cho HS; Cho SJ; Jo SA; Jo I
PLoS One; 2015; 10(9):e0138590. PubMed ID: 26375285
[TBL] [Abstract][Full Text] [Related]
9. (-)-Epigallocatechin gallate reduces transforming growth factor beta-stimulated HSP27 induction through the suppression of stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts.
Hayashi K; Takai S; Matsushima-Nishiwaki R; Hanai Y; Kato K; Tokuda H; Kozawa O
Life Sci; 2008 May; 82(19-20):1012-7. PubMed ID: 18407296
[TBL] [Abstract][Full Text] [Related]
10. (-)-epigallocatechin gallate inhibits endothelin-1-induced C-reactive protein production in vascular smooth muscle cells.
Wang CJ; Liu JT; Guo F
Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):669-75. PubMed ID: 20346058
[TBL] [Abstract][Full Text] [Related]
11. A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer.
Sukhthankar M; Yamaguchi K; Lee SH; McEntee MF; Eling TE; Hara Y; Baek SJ
Gastroenterology; 2008 Jun; 134(7):1972-80. PubMed ID: 18549879
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells.
Chen C; Shen G; Hebbar V; Hu R; Owuor ED; Kong AN
Carcinogenesis; 2003 Aug; 24(8):1369-78. PubMed ID: 12819184
[TBL] [Abstract][Full Text] [Related]
14. Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-kappaB in human prostate carcinoma DU-145 cells.
Vayalil PK; Katiyar SK
Prostate; 2004 Apr; 59(1):33-42. PubMed ID: 14991864
[TBL] [Abstract][Full Text] [Related]
15. Epigallocatechin-3-gallate inhibits proliferation of human aortic smooth muscle cells via up-regulating expression of mitofusin 2.
Shu Z; Yu M; Zeng G; Zhang X; Wu L; Tan X
Eur J Cell Biol; 2014 Apr; 93(4):137-44. PubMed ID: 24880525
[TBL] [Abstract][Full Text] [Related]
16. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis.
Mittal A; Pate MS; Wylie RC; Tollefsbol TO; Katiyar SK
Int J Oncol; 2004 Mar; 24(3):703-10. PubMed ID: 14767556
[TBL] [Abstract][Full Text] [Related]
17. Catechins inhibit angiotensin II-induced vascular smooth muscle cell proliferation via mitogen-activated protein kinase pathway.
Won SM; Park YH; Kim HJ; Park KM; Lee WJ
Exp Mol Med; 2006 Oct; 38(5):525-34. PubMed ID: 17079869
[TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin-3 gallate, a green tea catechin, attenuated the downregulation of the cardiac gap junction induced by high glucose in neonatal rat cardiomyocytes.
Yu L; Zhao Y; Fan Y; Wang M; Xu S; Fu G
Cell Physiol Biochem; 2010; 26(3):403-12. PubMed ID: 20798525
[TBL] [Abstract][Full Text] [Related]
19. Antifibrotic properties of epigallocatechin-3-gallate in endometriosis.
Matsuzaki S; Darcha C
Hum Reprod; 2014 Aug; 29(8):1677-87. PubMed ID: 24876174
[TBL] [Abstract][Full Text] [Related]
20. The antioxidant (-)-epigallocatechin-3-gallate inhibits activated hepatic stellate cell growth and suppresses acetaldehyde-induced gene expression.
Chen A; Zhang L; Xu J; Tang J
Biochem J; 2002 Dec; 368(Pt 3):695-704. PubMed ID: 12223099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
